Donaldson L, Grant I S, Naysmith M R, Thomas J S
Department of Anaesthetics, Ninewells Hospital, Dundee, UK.
Intensive Care Med. 1998 Jun;24(6):626-30. doi: 10.1007/s001340050627.
To investigate any relationship between the pathological features of amiodarone-induced pulmonary toxicity (APT) and clinical use of amiodarone in patients dying from acute respiratory distress syndrome (ARDS).
Retrospective study. Review of clinical and pathological findings of patients dying from ARDS.
Intensive Care Unit (ICU) and Pathology Department of University hospital.
Ten patients with clinical diagnosis of ARDS, who died in ICU and underwent post mortem examination.
Case note review of clinical details; independent review of histological specimens.
Over a 3-year period, ten patients underwent post mortem examination, of whom seven had received amiodarone. Three patients who received longer than 48 h of amiodarone had histological changes of widespread lipoid pneumonia, a recognised pattern of APT.
Acute amiodarone pulmonary toxicity is a definite pathological entity in ICU patients. High oxygen concentrations may be a risk factor, while pre-existing pathology, e. g. ARDS, may mask its development. Amiodarone should be used with caution in this group of patients.
研究胺碘酮所致肺毒性(APT)的病理特征与胺碘酮在死于急性呼吸窘迫综合征(ARDS)患者中的临床应用之间的关系。
回顾性研究。回顾死于ARDS患者的临床和病理检查结果。
大学医院重症监护病房(ICU)和病理科。
10例临床诊断为ARDS且在ICU死亡并接受尸检的患者。
查阅临床细节病历;独立复查组织学标本。
在3年期间,10例患者接受了尸检,其中7例接受了胺碘酮治疗。3例接受胺碘酮治疗超过48小时的患者出现广泛类脂性肺炎的组织学改变,这是一种公认的APT模式。
急性胺碘酮肺毒性在ICU患者中是一种明确的病理实体。高氧浓度可能是一个危险因素,而既往存在的病理状况,如ARDS,可能掩盖其发展。在这类患者中应谨慎使用胺碘酮。